Evidence map›Paper›PMID 39828902›Full record

ReviewThe FEBS journal2025

PI5P4K inhibitors: promising opportunities and challenges.

Koh Takeuchi, Lisa Nagase, Shun Kageyama, Hirotaka Kanoh, Masashi Oshima, Aki Ogawa-Iio, Yoshiki Ikeda, Yuki Fujii, Sei Kondo, Natsuki Osaka and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Koh TakeuchiGraduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Japan.ORCID https://orcid.org/0000-0002-6227-4627
Lisa NagaseStructural Biology Research Center, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Japan.
Shun KageyamaInstitute for Advanced Biosciences, Keio University, Tsuruoka, Japan.
Hirotaka KanohInstitute for Advanced Biosciences, Keio University, Tsuruoka, Japan.
Masashi OshimaDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, OH, USA.
Aki Ogawa-IioDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, OH, USA.
Yoshiki IkedaInstitute for Integrated Cell-Material Sciences, Kyoto University, Sakyo-ku, Japan.
Yuki FujiiDivision of Hematology and Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, OH, USA.
Sei KondoInstitute for Advanced Biosciences, Keio University, Tsuruoka, Japan.
Natsuki OsakaInstitute for Advanced Biosciences, Keio University, Tsuruoka, Japan.
Takeshi MasudaInstitute for Advanced Biosciences, Keio University, Tsuruoka, Japan.
Tsukasa IshiharaBiomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan.
Yoshikazu NakamuraDepartment of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, Chiba, Japan.
Yoshihisa HirotaDepartment of Bioscience and Engineering, College of Systems Engineering and Science, Shibaura Institute of Technology, Minuma-ku, Japan.
Takehiko SasakiDepartment of Biochemical Pathophysiology, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Japan.
Toshiya SendaStructural Biology Research Center, Institute of Materials Structure Science, High Energy Accelerator Research Organization (KEK), Tsukuba, Japan.ORCID https://orcid.org/0000-0002-5153-928X
Atsuo T SasakiInstitute for Advanced Biosciences, Keio University, Tsuruoka, Japan.ORCID https://orcid.org/0000-0003-2963-4501

Funding

Mechanistic role of phosphatidylinositol 5-phosphate 4-kinase beta in GTP-dependent lysosomal acidification for stress-resilient cell growth and metabolismR01GM144426 · NIGMS · UNIVERSITY OF CINCINNATI · PI Atsuo Sasaki · 2023 to 2026
$1.7M
Astellas Foundation for Research on Metabolic DisordersCREST Program JPMJCR20H6kCSR NIH HHS R01GM144426Human Frontier Science Program RGP0028/2022Japan Agency for Medical Research and Development 22ama221112h0001Japan Agency for Medical Research and Development 24gm1610003h0204Japan Agency for Medical Research and Development JP23ama121001Japan Agency for Medical Research and Development JP23gm1710007Japan Science and Technology AgencyJapan Society for the Promotion of Science 20H03165Japan Society for the Promotion of Science 22J12765Japan Society for the Promotion of Science 22K18374Japan Society for the Promotion of Science 23K05683Naito FoundationNIGMS NIH HHS R01 GM144426Takeda Science FoundationTerumo Life Science Foundation 23-III4028
6 · The paper itself

Abstract

Phosphatidylinositol 5-phosphate 4-kinases (PI5P4K), also known as type II PIPKs or PIPKIIs, convert the lipid second messenger PI5P to PI(4,5)P

Indexed as

NeoplasmsPhosphotransferases (Alcohol Group Acceptor)Protein Kinase InhibitorsAdenosine TriphosphateAnimalsHumansIsoenzymesNeurodegenerative DiseasesAdenosine TriphosphateIsoenzymesPhosphotransferases (Alcohol Group Acceptor)Protein Kinase Inhibitorscancerdrug developmentphosphoinositidePI3KPI4P5K/PIPKI/Type I PIPKPI5P4K/PIPKII/Type II PIPKscaffolding function

Identifiers

PMID39828902
PMCPMC12276927

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.